总的来说，值得授予专利的发明和发现是在制药和生物技术领域，在该领域每年都能推出价值可达数十亿美元，影响重大的新药。
By and large, the inventions and discoveries worth patenting are those in the pharmaceutical and biotech fields, where the pay-off for blockbuster drugs can amount to billions of dollars a year.
制药、生物技术、电子、IT和化工企业受到的冲击最为严重。
Pharmaceutical, biotechnology, electronics, IT and chemicals firms are being hit hardest.
生物仿制制药是对生物技术制药进行的非专利仿制(尽管不是完全一致的复制)。
Biosimilars are generic impersonations (although not identical copies) of biotech drugs.
重点是：生物技术可能已经早早的占据了制药行业的地位，但是其大的兴旺应该在于主流化学品的制造。
The point of the parable is this:biotechnology may have cut its teeth on medicines, but the big bucks are likelyto be in bulk chemicals.
但他也表示，这次他非常谨慎地看待新仿制药物的前景，因为生物技术药物很难仿制。
But he also said he was more cautious about the promise of generics this time, because biotech medicines were not easy to copy.
辉瑞公司上周宣布，已与罗氏和Alnylam一道，就这种形式的RNAi药物运输工具与加拿大生物技术Tekmira制药公司达成一笔交易。
Pfizer last week announced a deal with Canadian biotech Tekmira Pharmaceuticals Corp for this type of delivery vehicle for its RNAi drugs, joining Roche and Alnylam.
这家生物制药公司去年进行了两笔重大并购——买下了制药公司Gloucester和生物技术公司Abraxis——以推进其成为肿瘤治疗领域领导者的目标。
The biopharmaceutical company made two major acquisitions last year — the pharmaceutical company Gloucester and biotech firm Abraxis — to advance its goal of becoming an oncology leader.
帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。
Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.
另一个趋势是，在当前萧条的市场中让中等的生物技术公司略感希望的是，制药公司现在更倾向全资收购，而不再是代价不菲的合作或授权。
A trend in the past year, especially with the depressed market cap of small to medium biotechs, is the straight acquisition of a company rather than entry into an expensive collaboration or license.
这为大型制药公司的研究实验室如何陷入麻烦提供了解释：从传统化学转向新兴科学——生物技术。
This points to one explanation for how Big Pharma's research laboratories got into trouble: the shift from conventional chemistry to the "new science" of biotechnology.
随着时间的推移，这可能会推出充分的巩固，在制药、生物技术和通用公司之间。
This may roll out as a full consolidation, over time, between pharma, biotech and generics companies.
我不喜欢大型制药公司和生物技术公司的天花乱坠的广告以及其它五花八门的推销术，但是制药产业已经为提高世界健康水平作出了巨大的贡献。
I do not like the hype and some other salesmanship of big pharma and bio-tech companies, but this industry has made enormous contributions to raising world health.
突出生物技术在生物制药工程中的应用。
This program is characterized by the application of biotechnology in bio-pharmaceutical engineering.
基于蛋白复合物制备而得的生物技术制剂具有难于仿制的特点，因此世界制药巨头们开始对生物制剂展示极大兴趣。
The world's pharmaceutical giants are aflutter over "biologics" - protein compounds used to make drugs that are difficult to copy into generic versions.
该方案的几个方面也将感兴趣的制药和生物技术产业。
Several aspects of the program will also be of interest to the pharmaceutical and biotechnology industry.
本文综述了现代生物技术在制药、食品、农业及环境等领域的应用及发展前景。
This article gives an overview of the application and development prospects of modern biotechnology in pharmaceutical industry, food, agriculture and environment fields.
在制药、生物技术和食物加工行业，各种成份被传送、混合、加热和冷却。
In the pharmaceutical, biotech and food processing industries, ingredients are transported, mixed, heated and cooled.
本文结合生物技术制药课程实际情况，提出了综合性实验的设计方案，总结了综合性实验的实践管理经验。
Based on the actuality of biotechnological pharmaceutics teaching in our university, this paper proposes the design scheme and management experience of integrated experiments.
生物技术蓬勃发展并作用于医药领域，形成了全新的生物制药产业。
The flourishing development of biotechnology and its function in the medicine field have resulted in a wholly-new pharmaceutics industry-biopharmaceutics.
1990年代，生物技术在北加州迅猛发展，部分原因是电脑在分子工程和制药研究领域所起的作用。
In the 1990s, biotechnology blossomed in northern California, partly because of the role computers play in molecular engineering and pharmaceutical research.
因为这就意味着，一旦特许药的成本上升，制药公司就只能完全依赖与生物技术公司的合作关系了。
It would mean relying entirely on partnerships with biotech companies when the cost of licensing-in drugs is rising.
在制药和生物技术领域的最新成就并未在数字领域被复制。
Its more recent prowess in pharmaceuticals and biotechnology has not been emulated in the digital sphere.
对生物技术制药课程在教学内容和教学方法上的改进进行总结；
This paper discusses the teaching improvement and practice of Biotechnological Pharmaceutics in teaching contents and methods.
本发明属于生物技术制药技术领域。
The invention belongs to biotechnology pharmacy technology field.
具有下游分离技术基本知识以及生物技术制药基本知识。
A basic knowledge of the downstream separation technology and biotechnology pharmaceutical basic knowledge.
我们的客户和技术转让合作伙伴包括大部分世界领先的制药、生物技术和学术研究实验室。
Our customers and technology transfer partners include most of the world's leading pharmaceutical, biotechnology and academic research laboratories.
最近，为了满足不断增加的提高生产力的需求，制药和生物技术行业发生了根本性的变化。
Recently, the pharmaceutical and biotech industry has undergone fundamental changes as it has responded to increased productivity demands.
最近，为了满足不断增加的提高生产力的需求，制药和生物技术行业发生了根本性的变化。
Recently, the pharmaceutical and biotech industry has undergone fundamental changes as it has responded to increased productivity demands.
应用推荐